Does iodine fortification affect the risk of atrial fibrillation in incident hyperthyroidism? A national register-based cohort

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Dokumenter

  • Fulltext

    Forlagets udgivne version, 671 KB, PDF-dokument

Objective
Iodine fortification (IF) induces an initial increase followed by a decrease in the incidence of hyperthyroidism in the general population. Within the population of hyperthyroid patients, the sex-, age- and subtype distribution changes after IF. The risk of atrial fibrillation (AF) in hyperthyroid patients may be influenced by these factors. Therefore, we aimed to examine how the association between incident hyperthyroidism and AF was affected by IF increasing the population iodine intake from moderate-mild iodine deficiency to low adequacy.

Design, Patients and Measurements
Incident hyperthyroid patients were included at the date of first inpatient or outpatient diagnosis, and AF diagnoses within 3 months before to 6 months after the index date were identified in Danish nationwide registers, 1997–2018. The relative risk (RR) of AF each calendar year (reference: 1997; IF introduced: 2000) was analyzed in Poisson regression models adjusted for age, sex, educational level, geographic region, and comorbidities.

Results
Overall, in 62,201 patients with incident hyperthyroidism 7.9% were diagnosed with AF. There was a minor nonsignificantly increased risk of AF during the first years after IF followed by a gradual decrease to RR 0.76 (0.62–0.94) in 2017. There were no statistically significant differences in the development in the risk of AF by sex, age group, or geographic region.

Conclusions
Results indicate that IF may reduce the risk of concomitant AF in hyperthyroid patients. If these results are confirmed, IF may not only reduce the population incidence of hyperthyroidism but also reduce the burden of morbidity in the remaining hyperthyroid patients.
OriginalsprogEngelsk
TidsskriftClinical Endocrinology
Vol/bind100
Udgave nummer5
Sider (fra-til)502-510
ISSN0300-0664
DOI
StatusUdgivet - 2024

Bibliografisk note

Funding Information:
The authors would like to thank Dorthe Corfitzen Pedersen for graphical assistance. The study received financial support from The Danish Heart Foundation grant no. 20‐R141‐A9683‐22174. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Publisher Copyright:
© 2024 The Authors. Clinical Endocrinology published by John Wiley & Sons Ltd.

ID: 387438779